GlassScriptPhysician profile
Nicholas O Mclean
NPI 1205193331
$13,908.33
in general payments reported to CMS, 2019-2025
45 companies · $2,238 in 2025
The $2,238 reported for 2025 was more than what 90% of Nephrology (Internal Medicine) providers received nationally (typical 2025 total: $311).
See the full distribution for Nephrology (Internal Medicine)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,972 · 2020: $1,124 · 2021: $1,288 · 2022: $2,674 · 2023: $2,372 · 2024: $2,240 · 2025: $2,238.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $6,467 · Consulting Fee: $175 · Education: $140 · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $68.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $6,467.16 |
| Consulting Fee | $175.00 |
| Education | $140.24 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $68.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $1,483.18 | 2019-2025 | Farxiga, Lokelma, Flumist Quadrivalent |
| Otsuka America Pharmaceutical, INC. | $1,377.76 | 2019-2025 | Jynarque |
| Alexion Pharmaceuticals, INC. | $1,354.61 | 2019-2025 | Ultomiris |
| Mallinckrodt Hospital Products INC. | $968.29 | 2020-2025 | Acthar, Terlivaz |
| Amgen INC. | $935.79 | 2019-2025 | Tavneos, Parsabiv, Aranesp |
| Vifor Pharma, INC. | $814.91 | 2019-2025 | Veltassa |
| Travere Therapeutics, INC. | $570.33 | 2022-2025 | |
| Aurinia Pharma U.S., INC. | $554.08 | 2021-2025 | Lupkynis |
| Bayer Healthcare Pharmaceuticals INC. | $531.89 | 2021-2024 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $481.91 | 2022-2025 | Jardiance |
| Novartis Pharmaceuticals Corporation | $465.78 | 2019-2025 | |
| Akebia Therapeutics INC | $424.99 | 2019-2025 | Vafseo |
| Ani Pharmaceuticals, INC. | $369.41 | 2022-2025 | Purified Cortrophin Gel |
| Novo Nordisk INC | $351.80 | 2023-2025 | Ozempic, Rybelsus, Wegovy |
| Mallinckrodt Enterprises LLC | $349.53 | 2019 |
Show all 43 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Horizon Therapeutics Plc | $321.61 | 2019-2023 | Krystexxa |
| Calliditas Therapeutics US INC. | $316.74 | 2022-2024 | Tarpeyo |
| Opko Pharmaceuticals, LLC | $301.39 | 2019-2023 | Rayaldee |
| Glaxosmithkline, LLC. | $250.26 | 2021-2025 | Benlysta, Jesduvroq |
| Fresenius USA Marketing, INC. | $173.67 | 2019-2025 | Velphoro, Velphoro |
| Daiichi Sankyo INC. | $151.66 | 2020-2024 | Injectafer |
| Shield Therapeutics INC | $139.33 | 2022-2025 | Accrufer |
| Takeda Pharmaceuticals U.S.A., INC. | $119.68 | 2020-2024 | Gattex |
| Janssen Pharmaceuticals, INC | $110.38 | 2020 | |
| Bard Peripheral Vascular, INC. | $106.67 | 2019-2021 | |
| Otsuka Pharmaceutical Development & Commercialization, INC. | $98.82 | 2023 | |
| Ardelyx, INC. | $98.07 | 2023-2024 | Ibsrela |
| Shire North American Group INC | $92.37 | 2019 | |
| Lilly USA, LLC | $82.77 | 2024-2025 | Jardiance |
| Becton, Dickinson and Company | $68.00 | 2023-2025 | Power-Trialysis |
| Scpharmaceuticals INC. | $65.63 | 2025 | |
| Apellis Pharmaceuticals, INC. | $50.49 | 2025 | Empaveli |
| Arbor Pharmaceuticals, INC. | $46.59 | 2019-2020 | |
| Cormedix INC. | $40.80 | 2024-2025 | Defencath, Defencath |
| Kyowa Kirin, INC. | $38.37 | 2023 | Crysvita |
| Argenx US, INC. | $37.61 | 2022-2023 | Vyvgart |
| Rockwell Medical, INC. | $36.28 | 2020 | |
| Veloxis Pharmaceuticals, INC. | $25.63 | 2022 | |
| Outset Medical INC | $23.67 | 2024 | |
| Amag Pharmaceuticals, INC. | $22.38 | 2019 | |
| Baxter Healthcare | $22.09 | 2024 | Renal - Pd |
| Genentech USA, INC. | $18.07 | 2025 | Gazyva |
| Biomerieux INC | $15.04 | 2019 |
2 companies reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Nicholas Mclean listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.